Stay updated with breaking news from Remo colarusso. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A partnership with rival Merck & Co. to help make the shots, forged at the urging of the U.S. government, hasn’t lived up to expectations. The companies are now engaged in arbitration. ....
Not Particularly For A Pandemic But The Supply Chain Was Ready lifescienceleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lifescienceleader.com Daily Mail and Mail on Sunday newspapers.
DCAT Week 2021 to take on industry education, innovation outsourcing-pharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outsourcing-pharma.com Daily Mail and Mail on Sunday newspapers.
Johnson and Johnson expects COVID-19 vaccine results soon but lags behind in production In 2021, Johnson & Johnson promised to supply 200 million doses to Covax and will supply another 300 million to Covax in 2022. Jan 15, 2021 13:04:11 IST Johnson & Johnson expects to release critical results from its COVID-19 vaccine trial in as little as two weeks a potential boon in the effort to protect Americans from the coronavirus but most likely won’t be able to provide as many doses this spring as it promised the federal government because of unanticipated manufacturing delays. If the vaccine can strongly protect people against COVID-19, as some outside scientists expect, it would offer big advantages over the two vaccines authorized in the United States. Unlike those products, which require two doses, Johnson & Johnson’s could need just one, greatly simplifying logistics for local health departments and clinics struggling to get shots in arms. What’s more, its ....